AdvanCell has raised a $315 million Series D financing to push a lead radiopharmaceutical candidate toward late-stage development while expanding isotope supply and manufacturing capacity. The round, described as oversubscribed, targets a core bottleneck for radiopharma programs: reliably securing production throughput for radionuclides at the scale required for clinical and commercial demand. The company’s capital plan is positioned to support phase III advancement for ADVC-001, a lead-212 prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Additional funding is earmarked for strengthening manufacturing infrastructure alongside clinical progression. The financing is likely to resonate across the radiopharmaceutical ecosystem, where supply constraints can be as limiting as clinical differentiation, and where investors increasingly price in manufacturing scale as a pathway to commercialization.